DBV Technologies (NASDAQ:DBVT) Price Target Raised to $47.00 at Citizens Jmp

DBV Technologies (NASDAQ:DBVT) had its price objective lifted by Citizens Jmp from $45.00 to $47.00 in a report released on Friday,Benzinga reports. They currently have a market outperform rating on the stock.

Several other equities research analysts also recently commented on DBVT. Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Sunday, February 8th. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research note on Thursday, December 18th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Guggenheim reissued a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $38.65.

DBV Technologies Trading Down 1.0%

DBV Technologies stock opened at $20.00 on Friday. The company has a market capitalization of $1.11 billion, a PE ratio of -3.83 and a beta of -0.97. DBV Technologies has a 12 month low of $5.30 and a 12 month high of $26.18. The stock has a 50-day moving average price of $21.58 and a two-hundred day moving average price of $17.22.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Thursday, March 26th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.96). The firm had revenue of $0.64 million for the quarter, compared to the consensus estimate of $1.06 million. DBV Technologies had a negative return on equity of 310.56% and a negative net margin of 2,606.83%. As a group, analysts predict that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Large investors have recently added to or reduced their stakes in the business. Allworth Financial LP bought a new stake in DBV Technologies in the fourth quarter worth approximately $32,000. Royal Bank of Canada acquired a new position in DBV Technologies in the fourth quarter valued at approximately $34,000. GAMMA Investing LLC boosted its holdings in shares of DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares in the last quarter. New York State Common Retirement Fund bought a new position in shares of DBV Technologies during the 3rd quarter worth approximately $34,000. Finally, Truvestments Capital LLC grew its position in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares during the period. Institutional investors and hedge funds own 71.74% of the company’s stock.

More DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.